Integra Lifesciences (IART) Given a $54.00 Price Target by Cantor Fitzgerald Analysts

Cantor Fitzgerald set a $54.00 price objective on Integra Lifesciences (NASDAQ:IART) in a research note released on Tuesday morning. The firm currently has a hold rating on the life sciences company’s stock.

Other research analysts also recently issued reports about the company. BTIG Research restated a buy rating and set a $69.00 target price on shares of Integra Lifesciences in a research note on Wednesday, September 12th. Oppenheimer restated a buy rating and set a $70.00 target price on shares of Integra Lifesciences in a research note on Wednesday, October 31st. BidaskClub upgraded Integra Lifesciences from a hold rating to a buy rating in a research note on Friday, October 19th. SunTrust Banks initiated coverage on Integra Lifesciences in a research note on Thursday, January 3rd. They set a buy rating and a $56.00 target price on the stock. Finally, Zacks Investment Research upgraded Integra Lifesciences from a sell rating to a hold rating in a research note on Tuesday, October 9th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the stock. Integra Lifesciences presently has a consensus rating of Hold and a consensus price target of $62.00.

IART stock traded up $0.01 on Tuesday, hitting $45.51. 515,697 shares of the company’s stock were exchanged, compared to its average volume of 847,712. Integra Lifesciences has a 12-month low of $42.14 and a 12-month high of $67.50. The company has a debt-to-equity ratio of 1.04, a current ratio of 3.20 and a quick ratio of 2.08. The company has a market cap of $3.93 billion, a price-to-earnings ratio of 23.46, a price-to-earnings-growth ratio of 1.29 and a beta of 0.93.

Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Wednesday, October 31st. The life sciences company reported $0.59 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.59. Integra Lifesciences had a return on equity of 16.99% and a net margin of 5.49%. The firm had revenue of $365.85 million for the quarter, compared to the consensus estimate of $367.89 million. During the same period in the previous year, the business earned $0.45 EPS. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. As a group, equities research analysts anticipate that Integra Lifesciences will post 2.39 earnings per share for the current year.

In other Integra Lifesciences news, major shareholder Richard E. Caruso sold 46,676 shares of the business’s stock in a transaction dated Wednesday, October 17th. The stock was sold at an average price of $63.19, for a total transaction of $2,949,456.44. Following the sale, the insider now owns 134,134 shares in the company, valued at approximately $8,475,927.46. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Barbara B. Hill acquired 3,705 shares of the firm’s stock in a transaction dated Monday, November 5th. The stock was bought at an average cost of $53.90 per share, with a total value of $199,699.50. Following the acquisition, the director now owns 63,381 shares in the company, valued at $3,416,235.90. The disclosure for this purchase can be found here. 5.10% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of IART. GSA Capital Partners LLP acquired a new position in shares of Integra Lifesciences in the 2nd quarter valued at about $538,000. FMR LLC lifted its holdings in shares of Integra Lifesciences by 11.8% in the 2nd quarter. FMR LLC now owns 11,078,120 shares of the life sciences company’s stock valued at $713,542,000 after buying an additional 1,166,483 shares during the period. Federated Investors Inc. PA acquired a new position in shares of Integra Lifesciences in the 2nd quarter valued at about $1,730,000. OppenheimerFunds Inc. lifted its holdings in shares of Integra Lifesciences by 30.8% in the 2nd quarter. OppenheimerFunds Inc. now owns 604,315 shares of the life sciences company’s stock valued at $38,924,000 after buying an additional 142,321 shares during the period. Finally, Laurion Capital Management LP acquired a new position in shares of Integra Lifesciences in the 2nd quarter valued at about $1,470,000. 85.90% of the stock is owned by institutional investors and hedge funds.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Further Reading: What is the downside to momentum investing?

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply